Cargando…

Mechanism of acquired 5FU resistance and strategy for overcoming 5FU resistance focusing on 5FU metabolism in colon cancer cell lines

Fluorouracil (5FU) is converted to its active metabolite fluoro-deoxyuridine monophosphate (FdUMP) through the orotate phosphoribosyl transferase (OPRT)-ribonucleotide reductase (RR) pathway and thymidine phosphatase (TP)-thymidine kinase (TK) pathway and inhibits thymidylate synthase (TS), leading...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suetsugu, Tomonari, Mori, Ryutaro, Futamura, Manabu, Fukada, Masahiro, Tanaka, Hideharu, Yasufuku, Itaru, Sato, Yuta, Iwata, Yoshinori, Imai, Takeharu, Imai, Hisashi, Tanaka, Yoshihiro, Okumura, Naoki, Matsuhashi, Nobuhisa, Takahashi, Takao, Yoshida, Kazuhiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7905524/ https://www.ncbi.nlm.nih.gov/pubmed/33649846 http://dx.doi.org/10.3892/or.2021.7978

Ejemplares similares

The inhibition of thymidine phosphorylase can reverse acquired 5FU-resistance in gastric cancer cells
por: Mori, Ryutaro, et al.
Publicado: (2018)

5-FU Metabolism in Cancer and Orally-Administrable 5-FU Drugs
por: Miura, Koh, et al.
Publicado: (2010)

The Role of Adjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma Patients with Pathological Positive Lymph Nodes After Neoadjuvant Chemotherapy Followed by Esophagectomy: a Single Institute Retrospective Analysis
por: Imai, Takeharu, et al.
Publicado: (2021)

Aspirin suppresses chemoresistance and enhances antitumor activity of 5-Fu in 5-Fu-resistant colorectal cancer by abolishing 5-Fu-induced NF-κB activation
por: Fu, Jinbo, et al.
Publicado: (2019)

Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery
por: De Angelis, Paula M, et al.
Publicado: (2006)

Evaluation of histopathological heterogeneity of colorectal cancer liver metastasis sites after preoperative chemotherapy
por: Matsuhashi, Nobuhisa, et al.
Publicado: (2022)

5-FU toxicity and nutritional deficiencies.
por: Stenram, U.
Publicado: (1993)

Fluorouracil (5-FU)-induced Cardiomyopathy
por: Thalambedu, Nishanth, et al.
Publicado: (2019)

The role of GLI1 for 5-Fu resistance in colorectal cancer
por: Zhang, Lining, et al.
Publicado: (2017)

Whole transcriptome sequence data of 5-FU sensitive and 5-FU resistant tumors generated in a mouse model of de novo carcinogenesis
por: Iacovides, Demetris, et al.
Publicado: (2018)

No effect of dose, hepatic function, or nutritional status on 5-FU clearance following continuous (5-day), 5-FU infusion.
por: Fleming, R. A., et al.
Publicado: (1992)

Predicting Agents That Can Overcome 5-FU Resistance in Colorectal Cancers via Pharmacogenomic Analysis
por: Huang, Tsui-Chin, et al.
Publicado: (2021)

Association of 5-FU Therapeutic Drug Monitoring to DPD Phenotype Assessment May Reduce 5-FU Under-Exposure
por: Dolat, Marine, et al.
Publicado: (2020)

Inhibition of CDK1 Reverses the Resistance of 5-Fu in Colorectal Cancer
por: Zhu, Yiping, et al.
Publicado: (2020)

SAHA Overcomes 5-FU Resistance in IFIT2-Depleted Oral Squamous Cell Carcinoma Cells
por: Regmi, Prabha, et al.
Publicado: (2020)

Downregulation of δ opioid receptor by RNA interference enhances the sensitivity of BEL/FU drug-resistant human hepatocellular carcinoma cells to 5-FU
por: TANG, BO, et al.
Publicado: (2016)

Downregulation of δ opioid receptor by RNA interference enhances the sensitivity of BEL/FU drug-resistant human hepatocellular carcinoma cells to 5-FU
por: Tang, Bo, et al.
Publicado: (2018)

Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) ± folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients
por: Bensmaïne, M A, et al.
Publicado: (2001)

Wnt pathway is involved in 5-FU drug resistance of colorectal cancer cells
por: He, Lingfeng, et al.
Publicado: (2018)

Combinational inhibition of EGFR and YAP reverses 5-Fu resistance in colorectal cancer
por: Huang, Changhao, et al.
Publicado: (2020)

Overexpression of sortilin is associated with 5‐FU resistance and poor prognosis in colorectal cancer
por: Blondy, Sabrina, et al.
Publicado: (2020)

Managing 5FU Cardiotoxicity in Colorectal Cancer Treatment
por: Anaka, Matthew, et al.
Publicado: (2022)

[Retracted] Downregulation of δ opioid receptor by RNA interference enhances the sensitivity of BEL/FU drug‑resistant human hepatocellular carcinoma cells to 5‑FU
por: Tang, Bo, et al.
Publicado: (2023)

Decreased FANCJ caused by 5FU contributes to the increased sensitivity to oxaliplatin in gastric cancer cells
por: Mori, Ryutaro, et al.
Publicado: (2012)

Over-activation of AKT signaling leading to 5-Fluorouracil resistance in SNU-C5/5-FU cells
por: Kim, Eun-Ji, et al.
Publicado: (2018)

The Akt Inhibitor ISC-4 Synergizes with Cetuximab in 5-FU-Resistant Colon Cancer
por: Allen, Joshua E., et al.
Publicado: (2013)

Ell3 stimulates 5-FU resistance in a breast cancer cell line
por: Kim, Isaac, et al.
Publicado: (2017)

Reversal Effect of Dihydromyricetin on Multiple Drug Resistance in SGC7901/5-FU Cells
por: Wu, Mingcai, et al.
Publicado: (2020)

Over-expression of EGFR regulated by RARA contributes to 5-FU resistance in colon cancer
por: Gu, Xin-Yue, et al.
Publicado: (2020)

Targeting REV7 effectively reverses 5-FU and oxaliplatin resistance in colorectal cancer
por: Sun, Xianjun, et al.
Publicado: (2020)

METTL3 antagonizes 5-FU chemotherapy and confers drug resistance in colorectal carcinoma
por: Li, Min, et al.
Publicado: (2022)

METTL3 antagonizes 5-FU chemotherapy and confers drug resistance in colorectal carcinoma
por: Li, Min, et al.
Publicado: (2023)

5-FU-induced cardiac toxicity - an underestimated problem in radiooncology?
por: Steger, Felix, et al.
Publicado: (2012)

5-FU induced cardiotoxicity: case series and review of the literature
por: Yuan, Cai, et al.
Publicado: (2019)

Halofuginone inhibits tumorigenic progression of 5-FU-resistant human colorectal cancer HCT-15/FU cells by targeting miR-132-3p in vitro
por: Wang, Chen, et al.
Publicado: (2020)

Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer
por: Rao, S, et al.
Publicado: (2005)

Quality of life in patients with advanced gastric cancer: a randomized trial comparing docetaxel, cisplatin, 5-FU (TCF) with epirubicin, cisplatin, 5-FU (ECF)
por: Sadighi, Sanambar, et al.
Publicado: (2006)

Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer
por: Saini, A, et al.
Publicado: (2003)

nal‐IRI+5‐FU/LV versus 5‐FU/LV in post‐gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients
por: Ueno, Makoto, et al.
Publicado: (2020)

Effect of Skimmed Milk on the Absorption and Metabolism of5-Fluorouracil (5-FU) in Animals
por: Ahmad, Maqsood, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_uu3ee241ekrbna7dkpih2fprpf